Antoni Sicras-Mainar

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6334922/publications.pdf

Version: 2024-02-01

1162367 1125271 18 199 8 13 citations g-index h-index papers 20 20 20 231 docs citations times ranked citing authors all docs

#	Article	lF	CITATIONS
1	Epidemiology and treatment of heart failure in Spain: the HF-PATHWAYS study. Revista Espanola De Cardiologia (English Ed), 2022, 75, 31-38.	0.4	20
2	All-cause community acquired pneumonia cost by age and risk in real-world conditions of care in Spain. Expert Review of Pharmacoeconomics and Outcomes Research, 2022, 22, 853-867.	0.7	3
3	Sick Leave and Costs in Active Workers with Chronic Osteoarthritis Pain in Spain: Outcomes of the OPIOIDS Real World Study. Open Access Rheumatology: Research and Reviews, 2022, Volume 14, 25-38.	0.8	2
4	Treatment persistence and exacerbations in patients with asthma initiating treatment with inhaled corticosteroids and beta-adrenergic agonists: retrospective cohort study. BMJ Open, 2022, 12, e053964.	0.8	2
5	Future projections of opioid use and cost in patients with chronic osteoarthritis pain in Spain. Therapeutic Advances in Musculoskeletal Disease, 2021, 13, 1759720X2110105.	1.2	4
6	Epidemiology and costs of depressive disorder in Spain: the EPICO study. European Neuropsychopharmacology, 2021, 50, 93-103.	0.3	28
7	Economic impact of treatment-resistant depression: A retrospective observational study. Journal of Affective Disorders, 2021, 295, 578-586.	2.0	24
8	Disease Burden and Costs in Moderate-to-Severe Chronic Osteoarthritis Pain Refractory to Standard of Care: Ancillary Analysis of the OPIOIDS Real-World Study. Rheumatology and Therapy, 2021, 8, 303-326.	1.1	9
9	Adherence to Desvenlafaxine Versus Usual Care and Its Impact on Health Outcomes: A Comparative Real-world Clinical Study. Clinical Drug Investigation, 2021, 41, 1055-1066.	1.1	O
10	Health outcomes and costs in patients with osteoarthritis and chronic pain treated with opioids in Spain: the OPIOIDS real-world study. Therapeutic Advances in Musculoskeletal Disease, 2020, 12, 1759720X2094200.	1.2	14
11	Potential interactions between pangenotypic direct-acting antivirals and concomitant cardiovascular therapies in patients with chronic hepatitis C virus infection. Journal of International Medical Research, 2020, 48, 030006052096465.	0.4	5
12	<p>Clinical and Economic Consequences of Inhaled Corticosteroid Doses and Particle Size in Triple Inhalation Therapy for COPD: Real-Life Study</p> . International Journal of COPD, 2020, Volume 15, 3291-3302.	0.9	4
13	Uso concomitante de antivirales de acción directa (AAD) y fármacos con acción sobre el sistema nervioso central: Consideraciones en el perfil actual del paciente con hepatitis C. Revista De Psicologia De La Salud, 2020, 0, 1551.	0.2	3
14	<p>Economic impact of delaying initiation with multiple-inhaler maintenance triple therapy in Spanish patients with chronic obstructive pulmonary disease</p> . International Journal of COPD, 2019, Volume 14, 2121-2129.	0.9	14
15	Prevalencia de las potenciales interacciones medicamentosas entre los antivirales de acción directa pangenotÃpicos y la medicación concomitante asociada a los pacientes con infección del virus de la hepatitis C crónica en España. GastroenterologÃa Y HepatologÃa, 2019, 42, 465-475.	0.2	8
16	The Effect of Quitting Smoking on Costs and Healthcare Utilization in Patients with Chronic Obstructive Pulmonary Disease: A Comparison of Current Smokers Versus Ex-Smokers in Routine Clinical Practice. Lung, 2014, 192, 505-518.	1.4	16
17	Influence of the CYP2D6 Isoenzyme in Patients Treated with Venlafaxine for Major Depressive Disorder: Clinical and Economic Consequences. PLoS ONE, 2014, 9, e90453.	1.1	9
18	Assessment of pharmacological strategies for management of major depressive disorder and their costs after an inadequate response to first-line antidepressant treatment in primary care. Annals of General Psychiatry, 2012, 11, 22.	1.2	8